Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Benign Hematology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week
Published in Benign Hematology

Journal Scan / Research · December 22, 2022

Factor IX Levels Following Etranacogene Dezaparvovec Gene Therapy in Patients With Hemophilia B

Blood Advances

 

 Save  Recommend
 Share

Additional Info

Blood Advances
Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy
Blood Adv 2022 Dec 09;[EPub Ahead of Print], A von Drygalski, E Gomez, A Giermasz, G Castaman, NS Key, SS Lattimore, FWG Leebeek, WA Miesbach, M Recht, RZ Gut, R Dolmetsch, PE Monahan, S Le Quellec, SW Pipe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated